These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22225965)

  • 21. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
    Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
    Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paliperidone: a new extended-release oral atypical antipsychotic.
    Dlugosz H; Nasrallah HA
    Expert Opin Pharmacother; 2007 Oct; 8(14):2307-13. PubMed ID: 17927485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
    Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
    Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular paliperidone palmitate.
    Hoy SM; Scott LJ; Keating GM
    CNS Drugs; 2010 Mar; 24(3):227-44. PubMed ID: 20155997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.
    Üçok A; Saka MC; Bilici M
    Nord J Psychiatry; 2015 Aug; 69(6):426-32. PubMed ID: 25549697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.
    Si TM; Zhang YL; Feng Y; Zhuo JM; Cai S; Zhang L
    Psychiatry Res; 2019 Apr; 274():301-305. PubMed ID: 30831454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.
    Kotler M; Dilbaz N; Rosa F; Paterakis P; Milanova V; Smulevich AB; Lahaye M; Schreiner A
    J Psychiatr Pract; 2016 Jan; 22(1):9-21. PubMed ID: 26813484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
    Brown B; Turkoz I; Mancevski B; Mathews M
    Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement.
    Na KS; Kim CE; Kim YS; Lee JI; Han WS; Kang UG; Park DH; Kim B; Jung HY; Yoon JS; Lim SW
    Hum Psychopharmacol; 2013 Mar; 28(2):107-16. PubMed ID: 23417736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
    Carter NJ
    Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.